CLINICAL_TRIALS
withdrawal
· 2024-08-09
Clinical Trial Update: Voxelotor Brain Oxygenation and Neurocognitive Study [Phase 4]
Summary
Pfizer-sponsored Phase 4 study evaluating voxelotor for brain oxygenation and neurocognitive outcomes in sickle cell disease has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Sickle Cell Disease | Phase 4 | Status: WITHDRAWN